Company Filing History:
Years Active: 2024-2025
Title: Chris Ziebenhaus: Innovator in APOL1 Inhibitors
Introduction
Chris Ziebenhaus is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of APOL1 inhibitors. With a total of 2 patents to his name, Ziebenhaus is recognized for his innovative approaches to treating APOL1-mediated diseases.
Latest Patents
Ziebenhaus's latest patents focus on APOL1 inhibitors and methods of use. These patents detail compounds of formula (II) and include various stereoisomers, tautomers, and pharmaceutically acceptable salts. The patents also outline methods for preparing these compounds and strategies for inhibiting APOL1, which is crucial for treating related diseases and disorders.
Career Highlights
Currently, Chris Ziebenhaus is associated with Maze Therapeutics, Inc., where he continues to push the boundaries of medical research. His work is pivotal in developing therapies that target specific genetic conditions, showcasing his commitment to advancing healthcare solutions.
Collaborations
Ziebenhaus collaborates with talented professionals in his field, including Patrick Sang Tae Lee and Todd Jonathan August Ewing. These partnerships enhance the innovative potential of his research and contribute to the success of their projects.
Conclusion
Chris Ziebenhaus stands out as a key figure in the development of APOL1 inhibitors, with a focus on improving treatment options for patients. His contributions to the field of pharmaceuticals are invaluable and continue to inspire future innovations.